C
Carsten Schade Larsen
Researcher at Aarhus University Hospital
Publications - 106
Citations - 3347
Carsten Schade Larsen is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 28, co-authored 84 publications receiving 2726 citations. Previous affiliations of Carsten Schade Larsen include Aarhus University.
Papers
More filters
Journal ArticleDOI
Mortality Attributable to Smoking Among HIV-1–Infected Individuals: A Nationwide, Population-Based Cohort Study
Marie Helleberg,Shoaib Afzal,Gitte Kronborg,Carsten Schade Larsen,Gitte Pedersen,Court Pedersen,Jan Gerstoft,Børge G. Nordestgaard,Børge G. Nordestgaard,Niels Obel +9 more
TL;DR: In a setting where HIV care is well organized and antiretroviral therapy is free of charge, HIV-infected smokers lose more life-years to smoking than to HIV.
Journal ArticleDOI
Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study
Niels Obel,Henrik F. Thomsen,Gitte Kronborg,Carsten Schade Larsen,Per Hildebrandt,Henrik Toft Sørensen,Henrik Toft Sørensen,Jan Gerstoft +7 more
TL;DR: Compared with the general population, HIV-infected patients receiving HAART have an increased risk of ischemic heart disease, but the relative risk is stable up to 8 years after treatment initiation.
Journal ArticleDOI
Innate immune recognition and activation during HIV infection
TL;DR: Current knowledge on innate immune recognition and activation during HIV infection is presented based on studies in cell culture, non-human primates, and HIV-infected individuals, and the implications for the understanding of HIV immunopathogenesis are discussed.
Journal ArticleDOI
Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study
Line D Rasmussen,Margaret T May,Gitte Kronborg,Carsten Schade Larsen,Court Pedersen,Jan Gerstoft,Niels Obel +6 more
TL;DR: Overall, the age-standardised and relative risks of cardiovascular diseases, cancers, and severe neurocognitive disease did not increase substantially with time after HIV diagnosis or ART initiation, and calendar time.
Journal ArticleDOI
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Jesper Damsgaard Gunst,Nina Breinholt Stærke,Marie H. Pahus,Lena Hagelskjaer Kristensen,Jacob Bodilsen,Nicolai Lohse,Nicolai Lohse,Lars Skov Dalgaard,Dorthe Brønnum,Ole Fröbert,Bo Langhoff Hønge,Isik Somuncu Johansen,Ida Monrad,Christian Erikstrup,Christian Erikstrup,Regitze Rosendal,Emil Vilstrup,Theis Mariager,Dorthe Gaby Bove,Rasmus Offersen,Shakil Shakar,Sara Cajander,Nis Pedersen Jørgensen,Sajitha S. Sritharan,Peter Breining,Søren Jespersen,Klaus Leth Mortensen,Mads L. Jensen,Lilian Kolte,Giacomo S. Frattari,Carsten Schade Larsen,Merete Storgaard,Lars Peter Nielsen,Lars Peter Nielsen,Martin Tolstrup,Martin Tolstrup,Eva Aggerholm Sædder,Eva Aggerholm Sædder,Lars Østergaard,Lars Østergaard,Hien T. T. Ngo,Morten Hasselstrøm Jensen,Morten Hasselstrøm Jensen,Jesper F Højen,Mads Kjolby,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard +46 more
TL;DR: In this article, the transmembrane protease serine serine 2 (TMPRSS2) is essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.